Login / Signup

CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.

Lena AnderschJosefine RadkeAnika KlausSilke SchwiebertAnnika WinklerElisa SchumannLaura GrunewaldFelix ZirngiblCarina FlemmigMichael C JensenClaudia RossigAntonia JoussenAnton HenssenAngelika EggertJohannes H SchulteAnnette Künkele
Published in: BMC cancer (2019)
Both CD171 and GD2 are effective targets on human retinoblastoma cell lines, and CAR-T cell therapy is highly effective against retinoblastoma in vitro. Targeting of two different antigens by sequential CAR-T cell applications enhanced tumor cell killing and preempted tumor antigen loss in preclinical testing.
Keyphrases
  • cell therapy
  • induced apoptosis
  • stem cells
  • cell cycle arrest
  • mesenchymal stem cells
  • endothelial cells
  • dendritic cells